Type of information: Fundraising
Company: Advicenne (France)
Investors: IRDI SORIDEC Gestion (France) Cemag Invest (France) MI Care (Luxembourg) InnoBio Bpifrance (France) IXO Private Equity (France) private individuals.
Amount: €16 million
Funding type: financing round
Planned used: Advicenne plans to use these funds to advance its late-stage pipeline in nephrology and neurology, including:
Others: * On March 20, 2017, Advicenne, a late-stage biopharmaceutical company focused on the development of paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases, announced that it has closed a €16 million financing round. The fundraising was led by IRDI SORIDEC Gestion, Cemag Invest and MI Care alongside existing investors InnoBio (Bpifrance) and IXO Private Equity together with private individuals. Advicenne was established in 2007 in Nimes (France). Since its inception, the company has raised close to €30 million in equity from leading venture capital investors Innobio (Bpifrance), IXO Private Equity, IRDI SORIDEC Gestion, Cemag Invest and MI Care.
Therapeutic area: Kidney diseases - Renal diseases - Neurological diseases